#### **TECHNICAL SPECIFICATIONS**

Drug / Excipient					
Drug	Sirolimus				
Drug Dose	1.27 µg/mm²				
Drug Carrier	Phospholipid				
Balloon					
Balloon Material	Polyamide				
Cathether Design	RX/Monorail				
No. of folds	3**				
Compliance	Semi-compliant				

<sup>\*\* 2</sup> folds in 1.50 mm diameter


#### **Delivery System**

Shaft Diameter - Proximal 1.95 F Shaft Diameter - Distal 2.67 F Usable Catheter Length 140 cm Tip Profile 0.016" Nominal Pressure 8 bar Rated Burst Pressure 14 bar\* Guiding Catheter Compatibility 6F Guidewire Compatibility 0.014" maximum recommended Crossing profile (varies with size) 0.029"

We highly recommend preparing the vessel bed before treatment with MagicTouch - SCB \*Do Not Exceed RBP

#### **ORDERING INFORMATION**

Balloon Dia(mm)	Balloon Length (mm)							
	10	15	20	25	30	35	40	
1.50	CMN15010	CMN15015	CMN15020	CMN15025	CMN15030	CMN15035	CMN15040	
2.00	CMN20010	CMN20015	CMN20020	CMN20025	CMN20030	CMN20035	CMN20040	
2.25	CMN22510	CMN22515	CMN22520	CMN22525	CMN22530	CMN22535	CMN22540	
2.50	CMN25010	CMN25015	CMN25020	CMN25025	CMN25030	CMN25035	CMN25040	
2.75	CMN27510	CMN27515	CMN27520	CMN27525	CMN27530	CMN27535	CMN27540	
3.00	CMN30010	CMN30015	CMN30020	CMN30025	CMN30030	CMN30035	CMN30040	
3.50	CMN35010	CMN35015	CMN35020	CMN35025	CMN35030	CMN35035	CMN35040	
4.00	CMN40010	CMN40015	CMN40020	CMN40025	CMN40030	CMN40035	CMN40040	



\*The above diagram is just an illustration of the product.

Disclaimer: The law restricts these devices to sale by or on the order of a physician. Indications, contradictions, warnings can be found in the product labelling / IFU supplied with each device. For restricted use only in countries where product is registered with applicable health authorities.



# Concept Medical



## www.conceptmedical.com

## Concept Medical

# MagicTouch SCB SIROLIMUS COATED BALLOON CATHETER

SIROLIMUS

**CORONARY ARTERY DISEASE** 

### **MAGICTOUCH SCB**

MagicTouch - SCB is a Sirolimus Drug Coated Balloon catheter for the treatment of the coronary arteries; intended for treating In-Stent Restenosis, Small Vessels, Bifurcations lesions and De-Novo lesions.



#### **DE-NOVO LESIONS**

Concept of treating with leaving Nothing behind in patients with highly susceptible restenosis rate due to inherent disease conditions and comorbid conditions.



#### **BIFURCATION LESIONS**

Addresses the issue of metal to artery ratio by allowing one stent technique and less complications in side branch.



#### **IN-STENT RESTENOSIS**

Addresses the issue of restenosis by homogenous drug distribution without further increasing metal load in diffuse, focal and edge stenosis.



#### **SMALL VESSELS**

Helps in treating challenging anatomies in small diameter without loosing lumen diameter.

#### **UNIQUE COATING TECHNOLOGY**

MagicTouch - SCB is developed with Nanolute Technology which possesses unique circumferential coating technology that facilitates homogeneous drug distribution to target lesions





#### **COATING**

Circumferential Coating is performed under Low Pressure inflation leading to 100% surface area coating



**REFOLDING** 3 Folds




**INFLATION** 

Homogeneous Drug Delivery due to Circumferential Coating


### **NANOLUTE TECHNOLOGY**




Sirolimus sub-micron particle



Phospholipid drug carrier sub-micron particle









Dedicated spray coating on balloon surface

#### PHARMACOKINETIC STUDY

In ISR Lesion\*







#### SIROLIMUS DISTRIBUTION STUDY

DTF labelled Sirolimus was used to assess the drug distribution following DCB treatment\*

1 HR



DAY 3



DAY 7 30-40% within Media







30-40% below IEL

A: Adventitia; EEL: External Elastic Lamina; IEL: Internal Elastic Lamina; L: Lumen; M: Media \*EuroIntervention. 2013 May 20;9(1): 148-56

<sup>\*</sup>Study Ongoing